These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
249 related items for PubMed ID: 5110789
1. [Attempt at treating parkinsonism with L-dopa and Artane]. Stelmasiak Z, Lackowska H, Maksymowicz B. Pol Tyg Lek; 1971 Aug 23; 26(34):1325-6. PubMed ID: 5110789 [No Abstract] [Full Text] [Related]
2. [Effect of a combined L-Dopa and decarboxylase inhibitor (Ro 4-4602) therapy in parkinsonism patients. Quantitative analysis of bradykinesia using reaction times]. Kaufmann W, Butz P, Wiesendanger M. Dtsch Z Nervenheilkd; 1969 Dec 29; 197(1):85-100. PubMed ID: 5364658 [No Abstract] [Full Text] [Related]
3. [Therapeutic effects of L-dopa and trihexyphenidyl in Parkinson's disease--an examination by a double blind method]. Hirayama K, Uono M, Nakanishi T, Kato N, Nagao Y. Shinkei Kenkyu No Shimpo; 1971 Dec 29; 15(1):267-85. PubMed ID: 4937721 [No Abstract] [Full Text] [Related]
4. [Comparative value of L-dopa, amantadine, anticholinergics, and their combinations in parkinsonian syndromes]. Ciuca I, Bulandra R, Serbanesco A, Ninosu N. Rev Neurol (Paris); 1972 Aug 29; 127(2):305-8. PubMed ID: 4672049 [No Abstract] [Full Text] [Related]
5. [Factors which influence infavourably l-dopa treatment]. Presthus J. Tidsskr Nor Laegeforen; 1973 Oct 10; 93(28):2115-6. PubMed ID: 4590071 [No Abstract] [Full Text] [Related]
9. L-dopa in the treatment of Parkinsonism. Brezný I, Buranová D, Cernácek J, Trávniková M. Act Nerv Super (Praha); 1972 Oct 10; 14(2):96. PubMed ID: 5040182 [No Abstract] [Full Text] [Related]
11. [Evaluation of L-DOPA in Parkinsonism with special reference to the study by double-blind method]. Okajima T, Kubota A, Nakahara N, Takeda S, Shimomura K. Naika; 1972 Oct 10; 29(2):335-43. PubMed ID: 4552443 [No Abstract] [Full Text] [Related]
13. [Action of amantadine HCl alone and in combination with L-dopa on parkinsonism]. Danielczyk W, Korten JJ. Med Monatsschr; 1971 Oct 10; 25(10):472-9. PubMed ID: 5122447 [No Abstract] [Full Text] [Related]
14. [Present-day treatment of parkinsonism in the aged]. Siegfried J. Schweiz Rundsch Med Prax; 1973 Oct 02; 62(40):1202-3. PubMed ID: 4754539 [No Abstract] [Full Text] [Related]
15. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation]. Court J, Kase JC, Mena I, Palacios E. Rev Med Chil; 1973 Jun 02; 101(6):452-5. PubMed ID: 4764560 [No Abstract] [Full Text] [Related]
16. The pharmacology of parkinsonism (a review). Klawans HL. Dis Nerv Syst; 1968 Dec 02; 29(12):805-16. PubMed ID: 4388368 [No Abstract] [Full Text] [Related]
17. [Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)]. Birkmayer W. Wien Klin Wochenschr; 1969 Sep 26; 81(39):677-9. PubMed ID: 5344299 [No Abstract] [Full Text] [Related]
18. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study]. Wälzholz U, Schönfelder H. Nervenarzt; 1972 Oct 26; 43(10):531-2. PubMed ID: 4628192 [No Abstract] [Full Text] [Related]
19. L-dopa and amantadine for Parkinsonism. Drug Ther Bull; 1970 Aug 14; 8(17):65-7. PubMed ID: 5480244 [No Abstract] [Full Text] [Related]
20. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results]. De Divitiis E, Cerillo A, Tata MR, Decina A. Acta Neurol (Napoli); 1973 Aug 14; 28(2):208-12. PubMed ID: 4709076 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]